Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones

被引:79
作者
Hadjeri, M
Peiller, EL
Beney, C
Deka, N
Lawson, MA
Dumontet, C
Boumendjel, A
机构
[1] Fac Pharm Grenoble, CNRS, UMR 5063, Dept Pharmacochim Mol,Lab Chim Organ, F-38240 Meylan, France
[2] Univ Lyon 1, Fac Med Rockefeller, INSERM, Lab Cytol Analyt, F-69008 Lyon, France
关键词
D O I
10.1021/jm049876x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We report the synthesis of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones and their biological activity as antitumor agents. These molecules were initially evaluated for their ability to induce cell cycle arrest in the G2/M phase. Compounds that showed significant G2/M cell cycle arrest were tested for antiproliferative activity using both the MTT assay and the NCI in vitro 60 cell line human tumor screen. The 5-hydroxy-7-methoxy-2-phenyl-4-quinolone (3a) and 2-(3-fluorophenyl)-5-hydroxy-7-methoxy-4-quinolone (3f) were the most active in the cell cycle arrest test whereas 3f was found to be the most active in the MTT assay. In terms of structural requirements, we found that the presence of a 5-hydroxyl group, a 7-methoxy group, and an unsubstituted N1 were essential for the antimitotic activity. In accordance with the literature, a fluoro group at the 3'- or 2'-position and a methoxy or a chloro group at the 3'-position were found to be highly advantageous for both the cell cycle arrest and the antiproliferative activities.
引用
收藏
页码:4964 / 4970
页数:7
相关论文
共 24 条
  • [1] Structure-activity requirements for flavone cytotoxicity and binding to tubulin
    Beutler, JA
    Hamel, E
    Vlietinck, AJ
    Haemers, A
    Rajan, P
    Roitman, JN
    Cardellina, JH
    Boyd, MR
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) : 2333 - 2338
  • [2] Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance
    Boumendjel, A
    Di Pietro, A
    Dumontet, C
    Barron, D
    [J]. MEDICINAL RESEARCH REVIEWS, 2002, 22 (05) : 512 - 529
  • [3] Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1
  • [4] CODY V, 1988, PROGR CLIN BIOL RES
  • [5] Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
    deAzevedo, WF
    MuellerDieckmann, HJ
    SchulzeGahmen, U
    Worland, PJ
    Sausville, E
    Kim, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) : 2735 - 2740
  • [6] Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity
    Galmarini, CM
    Falette, N
    Tabone, E
    Levrat, C
    Britten, R
    Voorzanger-Rousselot, N
    Roesch-Gateau, O
    Vanier-Viornery, A
    Puisieux, A
    Dumontet, C
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 (06) : 902 - 908
  • [7] Alkylation of 2-phenyl-4-quinolones: Synthetic and structural studies
    Hadjeri, M
    Mariotte, AM
    Boumendjel, A
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2001, 49 (10) : 1352 - 1355
  • [8] Hamel E., 2018, Microtubule Proteins, P89
  • [9] Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO
  • [10] 2-T